N C Levitt

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Definition of an efficient synthetic poly(A) site.

N C Levitt, Daniel Briggs, A Gil et al. · Genes & Development · 1989 · 296 citations · Full text

Engineering, Genetics, Cellular Physiology +16

Potential Role for the BLM Helicase in Recombinational Repair via a Conserved Interaction with RAD51

Leonard Wu, Sally L. Davies, N C Levitt et al. · Journal of Biological Chemistry · 2001 · 289 citations · Full text

Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

N C Levitt, Ferry A.L.M. Eskens, Kenneth J. O’Byrne et al. · PubMed · 2001 · 136 citations

Tumor Response, Chemoprevention Strategy, Pharmacological Study +14

Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours

David Propper, Jeremy Braybrooke, D.J. Taylor et al. · Annals of Oncology · 1999 · 129 citations · Full text

Mitochondrial Function, Medicine, Pharmacology +6